- Home
- APRE vs BCLI Comparison
APRE vs BCLI Comparison
Compare APRE & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- BCLI
- Stock Information
- Founded
- APRE 2006
- BCLI 2000
- Country
- APRE United States
- BCLI United States
- Employees
- APRE N/A
- BCLI N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- APRE Health Care
- BCLI Health Care
- Exchange
- APRE Nasdaq
- BCLI Nasdaq
- Market Cap
- APRE 10.0M
- BCLI 9.8M
- IPO Year
- APRE 2019
- BCLI N/A
- Fundamental
- Price
- APRE $1.71
- BCLI $1.08
- Analyst Decision
- APRE Strong Buy
- BCLI Strong Buy
- Analyst Count
- APRE 2
- BCLI 1
- Target Price
- APRE $15.50
- BCLI $30.00
- AVG Volume (30 Days)
- APRE 50.9K
- BCLI 473.4K
- Earning Date
- APRE 08-11-2025
- BCLI 08-13-2025
- Dividend Yield
- APRE N/A
- BCLI N/A
- EPS Growth
- APRE N/A
- BCLI N/A
- EPS
- APRE N/A
- BCLI N/A
- Revenue
- APRE $1,284,475.00
- BCLI N/A
- Revenue This Year
- APRE N/A
- BCLI N/A
- Revenue Next Year
- APRE N/A
- BCLI N/A
- P/E Ratio
- APRE N/A
- BCLI N/A
- Revenue Growth
- APRE 33.27
- BCLI N/A
- 52 Week Low
- APRE $1.41
- BCLI $0.72
- 52 Week High
- APRE $5.01
- BCLI $6.45
- Technical
- Relative Strength Index (RSI)
- APRE 52.34
- BCLI 43.20
- Support Level
- APRE $1.48
- BCLI $1.08
- Resistance Level
- APRE $1.91
- BCLI $1.32
- Average True Range (ATR)
- APRE 0.16
- BCLI 0.10
- MACD
- APRE -0.00
- BCLI -0.01
- Stochastic Oscillator
- APRE 63.14
- BCLI 4.00
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.